Clinical Trial: The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study

Brief Summary: A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.

Detailed Summary: Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study
Sponsor: Wills Eye

Current Primary Outcome: Safety of Intravitreal Aflibercept Injection [ Time Frame: 6 months ]

Safety will be measured by the amount, significance and details of adverse events/reactions to the study drug.


Original Primary Outcome: Same as current

Current Secondary Outcome: Change in Vision Based on Letter Score [ Time Frame: 6 months ]

• Mean change from baseline in best-corrected ETDRS (Early Treatment of Diabetic Retinopathy Study) letter score


Original Secondary Outcome: Change in Vision Based on Letter Score [ Time Frame: 6 months ]

  • Mean change from baseline in best-corrected ETDRS (Early Treatment of Diabetic Retinopathy Study) letter score
  • Percentage of eyes with 20/40 or better vision
  • Percentage of eyes with ≥ 15-letter gain from baseline
  • Percentage of eyes with < 15-letter loss from baseline


Information By: Wills Eye

Dates:
Date Received: October 16, 2012
Date Started: October 2012
Date Completion:
Last Updated: February 22, 2017
Last Verified: February 2017